---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019097"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:03:11.592914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma Q1 update: FDA clears Phase 2 glioblastoma trial; cash $4.2M

## Summary
- FDA approved Phase 2 trial of Ropidoxuridine for glioblastoma; central IRB approved; first patient dosing expected Q2 2024.
- Cash and marketable securities at March 31, 2024 totaled approx. $4.2 million.
- Formed new wholly owned subsidiary Shuttle Diagnostics to develop predictive biomarker tests for prostate cancer.
- Obtained exclusive licenses from Georgetown University for predictive biomarker program and PSMA-B IP for metastatic prostate cancer.
- Finalizing site enrollment at up to six institutions for Phase 2 trial.

## SEC filing metadata
- accession: 0001493152-24-019097
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/0001493152-24-019097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019097
- JSON: https://secwatch.observer/filing/0001493152-24-019097.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019097.txt

## Key facts
- Earnings Releases
  Shuttle Pharmaceuticals Holdings, Inc. reported preliminary financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: preliminary results
  source text: On May 14, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), issued a press release providing a corporate update in connection with the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/0001493152-24-019097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.